Riskpilot← Back to searchSign inGet full accessMOLEK AB
ABActiveOrg 5566487855Korphoppsgatan 21Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20030 employees
Revenue 2025
SEK 23K
-49% vs 2024
EBITDA margin
-65.2%
-314% vs 2024
Equity ratio
51.8%
Financial strength
Net profit 2025
SEK 300K
+230% vs 2024
| Revenue | SEK 23K | -49% |
| EBITDA | SEK -15K | -314% |
| Net profit | SEK 300K | +230% |
| Total assets | SEK 782K | -20% |
| Equity | SEK 405K | +32% |
| Employees | 0 | — |
Legal name
MOLEK AB
Org number
5566487855
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
17 september 2003
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolagets verksamhet skall vara att marknadsföra och sälja medicinskteknisk laboratorieutrustning, företrädesvis osmometrar, cellräknare och blodmixer, service av sådana produktersamt därmed förenlig verksamhet,
Address
Korphoppsgatan 21
Phone
+46705133851
Email
roland.wik@molek.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 922 | 130 | 41 | 45 | 23 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 496 | −62 | 12 | 7 | −15 |
| Depreciation & amort. | −28 | −17 | −0 | −0 | −0 |
| EBIT | 468 | −79 | 12 | 7 | −15 |
| Net financials | 4 | 4 | 11 | 79 | 54 |
| Profit before tax | 354 | −8 | 23 | 119 | 386 |
| Tax | −76 | −0 | −7 | −28 | −86 |
| Net profit | 278 | −8 | 16 | 91 | 300 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 244 | 1 298 | 1 121 | 982 | 782 |
| Equity | 1 457 | 610 | 430 | 306 | 405 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 41 | 11 | 14 | 31 | 79 |
| Total debt | 41 | 11 | 14 | 31 | 79 |
EBITDA margin
-65.2%
This company
15.8%
Market median
-513% vs market
20212025
Equity ratio
51.8%
This company
38.2%
Market median
+36% vs market
20212025
Return on equity
74.1%
This company
18.4%
Market median
+303% vs market
20212025
Net profit margin
1304.3%
This company
8.1%
Market median
+16002% vs market
20212025
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20212025
Debt / equity
0.93×
This company
0.62×
Market median
+50% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
BR Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (1) | ||
LC | Audit | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2020 | |
| Former (2) | ||
| Board of Directors | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MOLEK AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lena Christina Normann | Audit | 0 companies |
| Björn Roland Wik | Chief Executive Officer | 0 companies |
| Christina Margareta Wik | Deputy Board Member | 0 companies |
| Karl Anders Molin | Board of Directors | 0 companies |
| Johan Gunnar Sällström | Deputy Board Member | 0 companies |